20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
Pharmaceutical Formulation Containing Gelling Agent
#2402Pharmaceutical Formulation Containing Gelling Agent
#2403Pharmaceutical Formulation Containing Gelling Agent
#2404PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROMORPHONE AND NALOXONE
#2405Opioid abuse-deterrent controlled release formulations
#2406Abuse-deterrent controlled release formulations
#2407PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM
#2408Methods of delivering pharmaceutical agents
#2409ORODISPERSIBLE FILM COMPOSITIONS
#2410Pharmaceutical Formulation Containing Gelling Agent
#2411Pharmaceutical Formulation Containing Gelling Agent
#2412METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS
#2413MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
#2414MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
#2415Phenylephrine formulations with improved stability
#2416Pharmaceutical compositions
#2417Pharmaceutical formulation containing gelling agent
#2418Pharmaceutical Formulation Containing Gelling Agent
#2419Pharmaceutical Formulation Containing Gelling Agent
#2420Pharmaceutical Formulation Containing Gelling Agent
#2421Pharmaceutical Formulation Containing Gelling Agent
#2422Pharmaceutical formulation containing gelling agent
#2423Tamper resistant dosage forms
#2424Tamper resistant dosage forms
#2425Tamper resistant dosage forms
#2426Oxycodone Compositions
#2427Oxycodone compositions
#2428ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#2429Analgesic composition including opioid analgesic and P7C3
#2430COMBINATION OF OPIOIDS AND ANTICANCER DRUGS FOR CANCER TREATMENT
#2431Controlled release hydrocodone formulations
#2432PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(EPSILON-CAPROLACTONE) AND POLYETHYLENE OXIDE
#2433Controlled release hydrocodone formulations
#2434Controlled release hydrocodone formulations
#2435Abuse-resistant controlled-release opioid dosage form
#2436Abuse-resistant controlled-release opioid dosage form
#2437Oxycodone Compositions
#2438INTRAVENOUS ADMINISTRATION OF TRAMADOL
#2439Nasal drug products and methods of their use
#2440ABUSE DETERRENT PHARMACEUTICAL COMPOSITION
#2441Compositions and methods for treating pruritus
#2442Abuse Resistant Drug Formulation
#2443ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM
#2444ORAL DRUG DELIVERY FORMULATIONS
#2445Abuse resistant oral dosage forms
#2446Abuse resistant drug formulation
#2447Process for making controlled release medical implant products
#2448METHODS OF ATTENUATING OPIOID TOLERANCE
#2449Morphine formulations
#2450CRUSH-RESISTANT TABLETS INTENDED TO PREVENT ACCIDENTAL MISUSE AND UNLAWFUL DIVERSION
#2451Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
#2452MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE
#2453Oligomer-opioid agonist conjugates
#2454NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#2455Pharmaceutical formulation containing gelling agent
#2456Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug
#2457Naloxone mono preparation and multilayer tablet
#2458Controlled release hydrocodone formulations
#2459Once-A day oxycodone formulations
#2460PHARMACEUTICAL COMPOSITION COMPRISING DIAMORPHINE FOR INTRANASAL ADMINISTRATION
#2461Tamper-resistant oral opioid agonist formulations
#2462Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
#2463Immediate Release Abuse Deterrent Tablet
#2464Polymorphic forms of naltrexone
#2465Sublingual apomorphine
#2466Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2467Controlled release hydrocodone formulations
#2468Controlled release hydrocodone formulations
#2469Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
#2470Crosslinked polymer nano-assemblies and uses thereof
#2471PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#2472ADMINISTRATION OF INTRAVENOUS IBUPROFEN
#2473Devices and methods for facilitating and controlling use of a medication
#2474Tamper resistant pharmaceutical formulations
#2475Orvinol and thevinol derivatives useful in the treatment of depression
#2476Treatments for depression and other diseases with a low dose agent
#2477Compositions comprising enzyme-cleavable oxycodone prodrug
#2478Oral drug delivery system
#2479Tamper resistant pharmaceutical formulations
#2480Methods of preparing tamper resistant pharmaceutical formulations
#2481Tamper resistant pharmaceutical formulations
#2482Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2483Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
#2484Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2485Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2486Peripherally acting opioid compounds
#2487Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
#2488BIOAVAILABILITY OF ORAL METHYLNALTREXONE INCREASES WITH A PHOSPHATIDYLCHOLINE-BASED FORMULATION
#2489Use of oxycodone for treating visceral pain
#2490Pharmaceutical formulation containing gelling agent
#2491Compositions and methods for weight loss in at risk patient populations
#2492Compositions comprising apomorphine and organic acids and uses thereof
#2493Opioid formulations
#2494METHODS FOR TREATING INFLAMMATION AND PAIN
#2495Tamper-resistant oral opioid agonist formulations
#2496PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
#2497Opioid-Containing Oral Pharmaceutical Compositions and Methods
#2498Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
#2499METHODS FOR TREATING EYE DISORDERS USING OPIOID RECEPTOR ANTAGONISTS
#2500Controlled release hydrocodone formulations
#2501Intranasal naloxone compositions and methods of making and using same
#2502Hybrid Opioid Compounds and Compositions
#2503Extruded extended release abuse deterrent pill
#2504Systems for treating an opioid-induced adverse pharmacodynamic response
#2505Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts
#2506Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations
#2507Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
#2508Bivalent ligands for the treatment of neurological disorders
#2509BIODEGRADABLE DRUG DELIVERY COMPOSITIONS
#2510THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS
#2511METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE
#2512Methods of modulating drug plasma levels using erythrohydroxybupropion
#2513Methods of treating overweight and obesity
#2514Implantable polymeric device for sustained release of dopamine agonist
#2515PERIPHERAL KAPPA RECEPTOR AGONISTS FOR REDUCING PAIN AND INFLAMMATION
#2516Peripheral opioid receptor antagonists and uses thereof
#2517Methods for treatment of Parkinson's disease
#2518Hydroxybupropion and related compounds as modulators of drug plasma levels
#2519Drug formulations having reduced abuse potential
#2520CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY
#2521Immediate Release Compositions and Methods For Delivering Drug Formulations Using Weak Acid Ion Exchange Resins In Abnormally High pH Environments
#2522Controlled release hydrocodone formulations
#2523Particulates
#2524Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
#2525Pharmaceutical formulation containing gelling agent
#2526Method for inhibiting growth of cancer cells
#2527Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
#2528Controlled Release of Phenolic Opioids
#2529Pharmaceutical Formulation Containing Gelling Agent
#2530COMPOSITIONS FOR AFFECTING WEIGHT LOSS
#2531Treatment of respiratory depression
#2532IN SITU CONTROLLED RELEASE DRUG DELIVERY SYSTEM
#2533Once-a-day oxycodone formulations
#2534Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
#2535Method for treating a GD2 positive cancer
#2536Bupropion as a modulator of drug activity
#2537Compositions and methods of using threohydroxybupropion for therapeutic purposes
#2538Methods for Detecting and Treating Rhinovirus Infection
#2539Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
#2540Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
#2541Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
#2542Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
#2543METHODS FOR TREATING VISCERAL FAT CONDITIONS
#2544Carboxamide bioisosteres of opiates
#2545Immediate release abuse-deterrent granulated dosage forms
#2546Immediate release abuse-deterrent granulated dosage forms
#2547Immediate Release Abuse-Deterrent Granulated Dosage Forms
#2548Immediate Release Abuse-Deterrent Granulated Dosage Forms
#2549Immediate Release Abuse-Deterrent Granulated Dosage Forms
#2550Oligomer-opioid agonist conjugates
#2551Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
#2552Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
#2553Acylated glucagon analogues
#2554Opioid agonist formulations with releasable and sequestered antagonist
#2555Gastric retentive tablet compositions
#2556Controlled release hydrocodone formulations
#2557CNS STIMULANT AND OPIOID RECEPTOR ANTAGONIST COMBINATION AS A NON-ADDICTIVE, NON-AVERSIVE AND SYNERGISTIC ANTI-OBESITY TREATMENT
#2558LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE-BASED POLYMERS AND THEIR MANUFACTURE
#2559TREATING POSTOPERATIVE NAUSEA AND VOMITING
#2560Pharmaceutical Compositions
#2561Pharmaceutical removal of neuronal extensions from a degenerating disc
#2562Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
#2563Dissolvable-chewable tablet
#2564Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2565Compositions and methods for the treatment of respiratory disorders
#2566Morphinan-derivatives for treating diabetes and related disorders
#2567Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#2568Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
#2569Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
#2570Sustained release formulation of naltrexone
#2571PHARMACEUTICAL COMBINATIONS OF HYDROCODONE AND NALTREXONE
#2572COMPOSITIONS AND METHODS FOR MINIMIZING OR REVERSING AGONIST-INDUCED DESENSITIZATION
#2573Methods and compositions for deterring abuse
#2574Morphine controlled release system
#2575Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
#2576Morphinan compounds
#2577Methods for treating depressive symptoms
#2578Abuse resistant forms of immediate release oxymorphone, method of use and method of making
#2579Abuse resistant forms of extended release hydrocodone, method of use and method of making
#2580Sublingual buprenorphine spray
#2581Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Uses Thereof
#2582Method of restoring the incretin effect
#2583Tamper Resistant Dosage Form Composition And Process Of Making The Same
#2584Tamper-resistant pharmaceutical dosage forms
#2585ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROMORPHONE, METHOD OF USE AND METHOD OF MAKING
#2586ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING
#2587Abuse resistant forms of extended release oxymorphone, method of use and method of making
#2588Abuse resistant forms of immediate release hydromorphone, method of use and method of making
#2589Oral film containing opiate enteric-release beads
#2590Biguanide compositions and methods of treating metabolic disorders
#2591Extruded immediate release abuse deterrent pill
#2592SYNTHESIS OF (R)-N-METHYLNALTREXONE
#2593MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN
#2594UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS
#2595ABUSE-PROOFED DOSAGE FORM
#25968-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
#2597Compositions of buprenorphine and μ Antagonists
#2598Coated solid dosage forms
#2599Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
#2600Conjugate of polyethylene gylcol and naloxone and pharmaceutical composition and use thereof
#2601Morphan and morphinan analogues, and methods of use
#2602Treating pain in patients with hepatic impairment
#2603ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYCODONE, METHOD OF USE AND METHOD OF MAKING
#2604Crystalline naloxol-peg conjugate
#2605Opioid polymer release system
#2606Tamper resistant dosage forms
#2607Tamper resistant dosage forms
#2608Tamper resistant dosage forms
#2609Controlled release hydrocodone formulations
#2610SUBSTITUTED CELLULOSE ACETATES AND USES THEREOF
#2611Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
#2612Pharmaceutical compositions with attenuated release of phenolic opioids
#2613Tamper resistant immediate release formulations
#2614Tamper resistant dosage forms
#2615ORAL LIQUID CONCENTRATE COMPRISING BROMPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN
#2616Buprenorphine-Wafer for Drug Substitution Therapy
#2617Opioid agonist/antagonist combinations
#2618FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF
#2619Modified release formulations containing drug—ion exchange resin complexes
#2620Pharmaceutical Compositions for the Deterrence and/or Prevention of Abuse
#2621Controlled release pharmaceutical compositions for prolonged effect
#2622Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine
#2623Transdermal therapeutic system having improved long-term wearing comfort
#2624Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
#26251-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
#2626Pharmaceutical compositions comprising a pH-dependent component and pH-raising agent
#2627Method and system for synthesizing nanocarrier based long acting drug delivery system for morphine
#2628Preparation for transnasal application
#2629OXYMORPHONE CONTROLLED RELEASE FORMULATIONS
#2630Opioid agonist/opioid antagonist/acetaminophen combinations
#2631Matrix for sustained, invariant and independent release of active compounds
#2632ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
#2633Pharmaceutical formulation containing gelling agent
#2634TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#2635Pharmaceutical Formulation Containing Gelling Agent
#2636Tamper-resistant pharmaceutical compositions of opioids and other drugs
#2637TRANSDERMAL THERAPEUTIC SYSTEM WITH A LOW TENDENCY TO SPONTANEOUSLY CRYSTALLIZE
#2638METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS
#2639Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
#2640SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#2641OPIOID ANALGESICS AND 3-HYDROXYACETANILIDE FOR TREATING PAIN
#2642Hyaluronic acid and its use for treating venous insufficiency and varicose veins
#2643Abuse resistant forms of extended release morphine, method of use and method of making
#2644Controlled release oral dosage form comprising oxycodone
#2645Controlled release hydrocodone formulations
#2646Sublingual films
#2647Pharmaceutical Formulation Containing Gelling Agent
#2648METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE
#2649Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
#2650Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
#2651Methods for treating gastrointestinal disorders associated with Parkinson's disease, autism, diabetic gastroparesis
#2652TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE
#2653Bioerodible sustained release drug delivery systems
#2654Opioid agonist/opioid antagonist/acetaminophen combinations
#2655Pharmaceutical formulation containing gelling agent
#2656Bivalent ligands for the treatment of neurological disorders
#2657Tamper resistant dosage form with bimodal release profile
#2658Tamper-resistant dosage form containing one or more particles
#2659Medication and treatment for disease
#2660METHODS FOR TREATING PRURITUS
#2661Methods for treating antipsychotic-induced weight gain
#2662Morphine and morphine precursors
#2663Robust controlled-release formulations
#2664Compositions and methods for inhibiting cytochrome P450 2D6
#2665ORALLY DISPERSIBLE DRUG FORMULATIONS
#2666TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS
#2667In situ gelling drug delivery system
#2668Compositions, dosage forms, and co-administration of an opioid agonist compound and a non-steroidal anti-inflammatory drug
#2669Abuse deterrent compositions and methods of making same
#2670Combination analgesic employing opioid agonist and neutral antagonist
#2671NEW NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS
#2672Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
#2673Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
#2674Morphinan compounds
#2675High dose buprenorphine compositions and use as analgesic
#2676Robust controlled-release peptide formulations
#2677Pharmaceutical Compositions
#2678Acrylic Polymer Formulations
#2679Use of opioid antagonists to attenuate endothelial cell proliferation and migration
#2680Compositions and methods for increasing insulin sensitivity
#2681Tablet capable of combatting misuse by injection
#2682Methods for administering weight loss medications
#2683DISSOLVING SOLID SOLUTION PERFORATOR PATCH FOR MIGRAINE TREATMENT
#2684METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM, DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY
#2685Morphinan compounds
#2686Compositions for controlling food intake and uses therefor
#2687Sustained release formulation of nalbuphine
#2688Methods related to the treatment of neurodegenerative and inflammatory conditions
#2689ADHESIVE SOLID GEL-FORMING FORMULATIONS FOR DERMAL DRUG DELIVERY
#2690COMPOSITIONS AND METHODS FOR REDUCING FOOD CRAVINGS
#2691Pharmaceutical compositions for treating or preventing pain
#2692Adhesive patch assembly with overlay liner and system and method for making same
#2693Titratable dosage transdermal delivery system
#2694Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency
#2695Compositions of a polyorthoester and an aprotic solvent
#2696Pharmaceutical preparation containing oxycodone and naloxone
#2697SEQUESTERED ANTAGONIST FORMULATIONS
#2698Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
#2699Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
#2700Method to treat premature ejaculation in humans